Background: The Oncotype DX Breast Cancer Assay is a 21-gene assay used to predict the likelihood of distant recurrence and the benefit of chemotherapy in patients with node-negative, tamoxifen-treated breast cancer. Prior studies demonstrated 7–19% discordance, or a difference between the recurrence score (RS) and tumor grade (TG) in breast cancer patients. BRCA mutated tumors (BRCA+) have been shown to be associated with higher RS as compared to BRCA-negative patients (BRCA–). Objectives: We developed a large Oncotype RS database to determine if the BRCA mutation status is associated with discordance. Methods: We identified 723 patients (32 [4%] mutation-positive and 691 [96%] mutation-negative patients) with early-stage, hormone-positive breast cancer treated between 2006 and 2018, with tumor characteristics available for analysis. Discordance was defined as one- or two-step difference between RS (low, intermediate, high risk) and TG (well [WD], moderately [MD], and poorly [PD] differentiated). Mutation positive was defined as BRCA1 deleterious mutation, BRCA2 deleterious mutation, BRCA mutation of unknown type, BRCA variant of undetermined significance (VUS) or other mutation (classified as other VUS). Number (%) or median were used to describe patient characteristics between groups and were compared by the Kruskal-Wallis test at a significance level of 5%. Results: Among these patients, there were 32 (4% of total) who were identified as mutation-positive. Of those patients, 16% had a documented deleterious mutation in BRCA1, 22% in BRCA2, 6% had a BRCA mutation of unknown type (either 1 or 2), 25% were BRCA VUS, and 31% other VUS (most commonly CHEK2 and ATM). The median RS was 23.5 in patients with deleterious BRCA mutations (1, 2 or unknown) versus 16 in patients in the BRCA-negative database, which was statistically significant (p < 0.01). One- and two-step discordance was present in 46 and 8%, respectively, of patients with deleterious BRCA mutations versus 53 and 11%, respectively, in the BRCA-negative database. Conclusions: Patients with deleterious BRCA mutations demonstrated no difference in rates of discordance as compared to BRCA-negative patients. We further demonstrated that patients with BRCA-positive tumors display higher RS than patients with BRCA-negative tumors.

1.
McAndrew
NP
,
Maxwell
KN
,
Stopfer
J
,
Powers
J
,
Brandt
AC
,
Long
JM
, et al
Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer
.
J Clin Oncol
.
2015
;
33
(
15_Suppl l
):
541
.
2.
Halpern
N
,
Sonnenblick
A
,
Uziely
B
,
Divinsky
L
,
Goldberg
Y
,
Hamburger
T
, et al
Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer
.
Int J Cancer
.
2017
;
140
(
9
):
2145
9
. .
3.
Shah
PD
,
Patil
S
,
Dickler
MN
,
Offit
K
,
Hudis
CA
,
Robson
ME
.
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status
.
Cancer
.
2016
;
122
(
8
):
1178
84
.
4.
Vocka
M
,
Zimovjanova
M
,
Bielcikova
Z
,
Tesarova
P
,
Petruzelka
L
,
Mateju
M
, et al
Estrogen receptor status oppositely modifies breast cancer prognosis in BRCA1/BRCA2 mutation carriers versus non-carriers
.
Cancers (Basel)
.
2019 May 28
;
11
(
6
).
pii:E738
.
5.
Lewin
R
,
Sulkes
A
,
Shochat
T
,
Tsoref
D
,
Rizel
S
,
Liebermann
N
, et al
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations
.
Breast Cancer Res Treat
.
2016
;
157
(
3
):
511
6
.
6.
Zimmerman
BS
,
Cascetta
KP
,
Ru
M
,
Eggert
L
,
Molot
MC
,
Nayak
A
, et al
Retrospective analysis of oncotype DX recurrence score (RS) and discordance in patients with node-negative, ER+ breast cancer with recurrence [abstract]
.
Cancer Res
.
2018
;
78
(
4 Suppl
):
P1-07-16
.
7.
Sparano
JA
,
Gray
RJ
,
Ravdin
PM
,
Makower
DF
,
Pritchard
KI
,
Albain
KS
, et al
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
.
The New Engl J Med
.
2019
;
380
(
25
):
2395
405
.
8.
Dodson
A
,
Okonji
D
,
Assersohn
L
,
Rigg
A
,
Sheri
A
,
Turner
N
, et al
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
.
Breast Cancer Res Treat
.
2018
;
168
(
1
):
249
58
. .
9.
Chappuis
PO
,
Goffin
J
,
Wong
N
,
Perret
C
,
Ghadirian
P
,
Tonin
P
, et al
A significant response to neoadjuvant chemotherapy in brca1/2 related breast cancer
.
J Med Genet
.
2002
;
39
(
8
):
608
10
. .
10.
Narod
SA
,
Metcalfe
K
,
Lynch
HT
,
Ghadirian
P
,
Robidoux
A
,
Tung
N
, et al
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?
Breast Cancer Res Treat
.
2013
;
138
(
1
):
273
9
.
11.
Rebbeck
TR
,
Kauff
ND
,
Domchek
SM
.
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers
.
J Natl Cancer Inst
.
2009
;
101
(
2
):
80
7
.
12.
Rebbeck
TR
,
Levin
AM
,
Eisen
A
,
Snyder
C
,
Watson
P
,
Cannon-Albright
L
, et al
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
.
J Natl Cancer Inst
.
1999
;
91
(
17
):
1475
9
.
13.
Eisen
A
,
Lubinski
J
,
Klijn
J
,
Moller
P
,
Lynch
HT
,
Offit
K
, et al
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study
.
J Clin Oncol
.
2005
;
23
(
30
):
7491
6
.
14.
Domchek
SM
,
Friebel
TM
,
Singer
CF
,
Evans
DG
,
Lynch
HT
,
Isaacs
C
, et al
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality
.
JAMA
.
2010
;
304
(
9
):
967
75
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.